|
Synonyms: Keytruda® | lambrolizumab | MK-3475
pembrolizumab is an approved drug (FDA (2014), EMA (2015))
Compound class:
Antibody
Comment: Pembrolizumab is the first-in-class, anti-PD-1 antibody to be approved by the US FDA.
Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody. Pembrolizumab is the first immuno-oncology therapeutic to be approved for use in cancers of any tissue type, so long as they express a specific genetic biomarker (i.e. high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) tumours). This is an important breakthrough, since up until this point FDA approvals, including earlier approvals for pembrolizumab, had always been restricted to certain tissue-specific cancers. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Included in GtoImmuPdb as it is an immune checkpoint inhibitor, not because it is a therapeutic for inflammatory conditions. Pembrolizumab is being evaluated in clinical trial in combination with the first-in-class anti-CD16A (FcγRIIIA)/CD30 bispecific tandem diabody AFM13 (a NK cell engaging strategy aimed at maximising ADCC - see NCT02665650, Phase 1) for relapsed/refractory classical Hodgkin lymphoma. |
